Book closure date

Ceo ResignedCeo Appointed ExternalManagement Changes View source PDF Explain this filing

ALBERTDAVD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-9.4%Reaction day

₹790.00

prior close

₹730.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-10.1% vs market

Pharmaceuticals peers, median of 162sector+0.0%-9.4% vs sector

On the reaction day the stock moved 10.1 pts less than Nifty Microcap 250 and 9.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.9

10m

-1.9

15m

-2.3

30m

-2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-9.4+0.7-10.1+0.0-9.4

Next day

-10.5+0.9-11.4+0.5-11.0

-8.6+0.6-9.2+0.0-8.6

-10.1-0.8-9.3-0.6-9.5

-9.2-0.4-8.9-0.1-9.2

-10.4+0.2-10.6+1.0-11.3

-10.6+1.4-12.1+0.8-11.5

15d

-8.8+4.2-13.0+1.1-9.9

-8.3+6.3-14.6+2.6-11.0

-11.2+11.3-22.5+6.8-18.0

+1.7+14.0-12.3+9.2-7.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Albert David Limited announced appointment of Mr. Amit Mahla as CEO effective May 12, 2026, filling a vacancy left by Mr. Umesh Manohar Kunte who resigned as Managing Director & CEO on December 18, 2025 (approximately 5 months prior). The company reported audited FY2026 results showing revenue of Rs 33,359.81 lakhs but a net loss of Rs 149.47 lakhs, a sharp decline from FY2025 profit of Rs 1,720.08 lakhs. The board recommended a final dividend of Rs 5 per share (50%) for FY2026, subject to shareholder approval at the 87th AGM on August 6, 2026. Record date for dividend is July 30, 2026.

Likely market impact

The company saw a significant turnaround from profit to loss in FY2026. The new CEO appointment after a 5-month vacancy brings experienced pharmaceutical leadership, which could be positive for strategic direction. However, the financial performance deterioration may concern investors in the near term despite the dividend announcement.